| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial
|
Derks, Marloes G M
|
|
|
18 |
9 |
p. 1211-1220
|
article
|
| 2 |
Androgen deprivation in prostate cancer: first do no harm
|
Saad, Fred
|
|
|
18 |
9 |
p. 1142-1144
|
article
|
| 3 |
Arsenic trioxide consolidation in APL
|
Das, Manjulika
|
|
|
18 |
9 |
p. e517
|
article
|
| 4 |
Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study
|
Wolthers, Benjamin O
|
|
|
18 |
9 |
p. 1238-1248
|
article
|
| 5 |
Concurrent chemotherapy and proton beam therapy in NSCLC
|
Das, Manjulika
|
|
|
18 |
9 |
p. e515
|
article
|
| 6 |
Correction to Lancet Oncol 2016; 17: 727–37
|
|
|
|
18 |
9 |
p. e510
|
article
|
| 7 |
Correction to Lancet Oncol 2017; 18: 1040–48
|
|
|
|
18 |
9 |
p. e510
|
article
|
| 8 |
Correction to Lancet Oncol 2017; 18: 917–28
|
|
|
|
18 |
9 |
p. e510
|
article
|
| 9 |
Correction to Lancet Oncol 2017; 18: 1182–91
|
|
|
|
18 |
9 |
p. 510
|
article
|
| 10 |
Correction to Lancet Oncol 2017; 18: 1274–84
|
|
|
|
18 |
9 |
p. e510
|
article
|
| 11 |
Correction to Lancet Oncol 2017; 18: e429
|
|
|
|
18 |
9 |
p. e510
|
article
|
| 12 |
CTLA-4 blockade in mesothelioma: ineffective or reason for optimism?
|
Thomas, Anish
|
|
|
18 |
9 |
p. 1150-1151
|
article
|
| 13 |
“Death is an adventure”: the power of terminal diagnosis
|
Lucas, Catherine
|
|
|
18 |
9 |
p. 1157-1158
|
article
|
| 14 |
Definition and recommendations for advance care planning: an international consensus supported by the European Association for Palliative Care
|
Rietjens, Judith A C
|
|
|
18 |
9 |
p. e543-e551
|
article
|
| 15 |
Fasting conditions in clinical oncology trials and drug labelling
|
Yu, Guo
|
|
|
18 |
9 |
p. e506
|
article
|
| 16 |
Fasting conditions in clinical oncology trials and drug labelling – Authors' reply
|
Lubberman, Floor J E
|
|
|
18 |
9 |
p. e507
|
article
|
| 17 |
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
|
Wasan, Harpreet S
|
|
|
18 |
9 |
p. 1159-1171
|
article
|
| 18 |
Genetic basis for response to cancer immunotherapy
|
Gruber, Karl
|
|
|
18 |
9 |
p. e521
|
article
|
| 19 |
Haploidentical donor transplants in ALL
|
Das, Manjulika
|
|
|
18 |
9 |
p. e516
|
article
|
| 20 |
Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
|
Duchesne, Gillian M
|
|
|
18 |
9 |
p. 1192-1201
|
article
|
| 21 |
Hypoglossal paresis caused by a solitary breast cancer metasasis at the basal skull
|
Eichbaum, Michael H R
|
|
|
18 |
9 |
p. e552
|
article
|
| 22 |
Individualised adaptive radiotherapy in liver cancer
|
Das, Manjulika
|
|
|
18 |
9 |
p. e520
|
article
|
| 23 |
Integrative sequencing of metastatic cancer
|
Venkatesan, Priya
|
|
|
18 |
9 |
p. e518
|
article
|
| 24 |
Liquorice: a treatment for all sorts?
|
Harding, Victoria
|
|
|
18 |
9 |
p. 1155
|
article
|
| 25 |
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial
|
Alderson, Derek
|
|
|
18 |
9 |
p. 1249-1260
|
article
|
| 26 |
New perspectives for TAS-102: TASK successful?
|
Loupakis, Fotios
|
|
|
18 |
9 |
p. 1139-1141
|
article
|
| 27 |
NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma
|
Elsada, Ahmed
|
|
|
18 |
9 |
p. 1153-1154
|
article
|
| 28 |
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|
Overman, Michael J
|
|
|
18 |
9 |
p. 1182-1191
|
article
|
| 29 |
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|
Pujade-Lauraine, Eric
|
|
|
18 |
9 |
p. 1274-1284
|
article
|
| 30 |
Our Short History
|
Denny, Victoria
|
|
|
18 |
9 |
p. 1158
|
article
|
| 31 |
Palliative care in Africa: a scoping review from 2005–16
|
Rhee, John Y
|
|
|
18 |
9 |
p. e522-e531
|
article
|
| 32 |
PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer
|
Sclafani, Francesco
|
|
|
18 |
9 |
p. 1141-1142
|
article
|
| 33 |
Primary medical therapy for BRAF V600E-mutant melanoma brain metastases—is this good enough?
|
Kruser, Tim J
|
|
|
18 |
9 |
p. e508
|
article
|
| 34 |
Primary medical therapy for BRAF V600E-mutant melanoma brain metastases—is this good enough? – Authors' reply
|
Davies, Michael A
|
|
|
18 |
9 |
p. e509
|
article
|
| 35 |
Protein biomarker for pancreatic ductal adenocarcinoma
|
Burki, Talha
|
|
|
18 |
9 |
p. e511
|
article
|
| 36 |
Questions on asparaginase-associated pancreatitis
|
Pemmaraju, Naveen
|
|
|
18 |
9 |
p. 1148-1149
|
article
|
| 37 |
Radiotherapy for the treatment of malignant pleural mesothelioma
|
de Perrot, Marc
|
|
|
18 |
9 |
p. e532-e542
|
article
|
| 38 |
Ready-to-use T cells for infection after stem-cell transplant
|
Gilbert, Judith A
|
|
|
18 |
9 |
p. e519
|
article
|
| 39 |
Redefining the molecular substructure of medulloblastoma
|
Benmaamar, Ramla
|
|
|
18 |
9 |
p. e514
|
article
|
| 40 |
Reduced-dose ipilimumab with standard-dose pembrolizumab: is less more?
|
Postow, Michael
|
|
|
18 |
9 |
p. 1144-1145
|
article
|
| 41 |
Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis
|
Lacas, Benjamin
|
|
|
18 |
9 |
p. 1221-1237
|
article
|
| 42 |
Selective internal radiotherapy in advanced colorectal cancer: only for right-sided tumours?
|
Schmoll, Hans-Joachim
|
|
|
18 |
9 |
p. 1138-1139
|
article
|
| 43 |
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
|
Long, Georgina V
|
|
|
18 |
9 |
p. 1202-1210
|
article
|
| 44 |
Surgery no better than observation for localised prostate cancer
|
Das, Manjulika
|
|
|
18 |
9 |
p. e512
|
article
|
| 45 |
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study
|
Kuboki, Yasutoshi
|
|
|
18 |
9 |
p. 1172-1181
|
article
|
| 46 |
The true value of altered fractionation in head and neck cancer
|
Nuyts, Sandra
|
|
|
18 |
9 |
p. 1147-1148
|
article
|
| 47 |
The Truth About Cancer
|
Burki, Talha Khan
|
|
|
18 |
9 |
p. 1156
|
article
|
| 48 |
Tobacco companies flout anti-tobacco laws in India
|
Guha, Paroma
|
|
|
18 |
9 |
p. e513
|
article
|
| 49 |
To promote maintenance or treatment, is that the question?
|
Bookman, Michael A
|
|
|
18 |
9 |
p. 1151-1152
|
article
|
| 50 |
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
|
Maio, Michele
|
|
|
18 |
9 |
p. 1261-1273
|
article
|
| 51 |
Tuning up adjuvant endocrine therapy: the TEAM trial
|
Martin, Miguel
|
|
|
18 |
9 |
p. 1145-1146
|
article
|
| 52 |
Turning taboos into action
|
The Lancet Oncology,
|
|
|
18 |
9 |
p. 1137
|
article
|
| 53 |
While We Still Have Time
|
Mariotti, Laura
|
|
|
18 |
9 |
p. 1156-1157
|
article
|
| 54 |
Why is survival after pembrolizumab affected by previous radiotherapy?
|
Manapov, Farkhad
|
|
|
18 |
9 |
p. e504
|
article
|
| 55 |
Why is survival after pembrolizumab affected by previous radiotherapy? – Authors' reply
|
Lee, Percy
|
|
|
18 |
9 |
p. e505
|
article
|
Journal description